Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.6152W HIGH $18.67
Volume
83.95 K
Value Traded
9.12 M
Short % Float
4.88%
Days to Cover
3.4
+8.79%Week
+5.69%1 Month
+15.85%3 Month
+82.6%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
917.76 M
EPS (TTM)
-0.67
P/E Ratio
-
Ent. Value
730.81 M
Total Shares
50.65 M
Float Shares
48.43 M
Insiders
4.39%
Institutions
89.79%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CYRX Catalyst Timeline
Dated clinical, regulatory and corporate events for CryoPort, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for CryoPort, Inc. Common Stock
273Total events
2Upcoming
112Tier-1 (high impact)
2010 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Manufacturing MilestoneCMC / Inspection
Planned launch of BioServices operations at Global Supply Chain Center in Paris, France
▲Partnership / LicenseCorporate
Cryoport's IntegriCell selected by Verismo Therapeutics to support KIR-CAR T cell therapy programs
▲Label ExpansionCASGEVYFDA Decision
FDA expands CASGEVY label to children as young as two
sickle cell disease and transfusion-dependent beta thalassemia in patients aged 2 years and oldersource ↗
▲Partnership / LicenseIntegriCellCorporate
Verismo Therapeutics selects Cryoport Systems' IntegriCell cryopreservation services
solid tumors and B cell disorderssource ↗
●Manufacturing MilestoneCMC / Inspection
Shipped first HE freezers made in China for China from Chengdu facility
◆FDA ApprovalFDA Decision
Three clients anticipating new therapy approval decisions in March and April 2026
▲FDA Filing AcceptedINO-3107FiledRegulatory Filing
FDA accepted BLA filing for INO-3107
Recurrent Respiratory Papillomatosissource ↗
▲Quarterly UpdateCorporate
Cryoport reports Q3 2025 financial results with 15% YoY revenue growth
▲Quarterly UpdateCorporate
Cryoport reports Q2 2025 financial results with 14% YoY revenue growth
▲Partnership / LicenseCorporate
Cryoport completes divestiture of CRYOPDP to DHL and enters strategic partnership
●BLA SubmissionRegulatory Filing
Two BLA filings for label/geographic expansions occurred post Q2 2025
▲Product LaunchPost-Market
MVE Biological Solutions launches next-generation SC 4/2V dry vapor shipper with integrated Condition Monitoring
▲Product LaunchPost-Market
MVE Biological Solutions launches next-generation SC 4/3V dry vapor shipper with integrated Condition Monitoring
▲Manufacturing MilestoneCMC / Inspection
Cryoport opens new Global Supply Chain Center near Charles de Gaulle Airport in Paris, France
▲REMS RemovedPost-Market
FDA removes REMS for approved BCMA- and CD19-directed CAR-T therapies
BCMA- and CD19-directed autologous CAR-T cell immunotherapiessource ↗
◆AcquisitionCorporate
DHL's anticipated acquisition of CRYOPDP expected to close in Q2 or Q3 2025
▲Partnership / LicenseCorporate
Cryoport enters strategic partnership with DHL Group, including DHL's anticipated acquisition of CRYOPDP
●BLA SubmissionRegulatory Filing
Six BLA/MAA filings occurred in Q1 2025 (three new therapies, three geographic expansions)
▲Partnership / LicenseCorporate
Strategic partnership with DHL Group and divestiture of CRYOPDP
▲Product LaunchPost-Market
Launch of IntegriCell Cryopreservation Solution with new facility in Houston
▲Other Regulator MilestoneEx-US Regulatory
PMDA approval of SanBio's AKUUGO for traumatic brain injury
chronic motor paralysis from traumatic brain injurysource ↗
▲FDA ApprovalFDA Decision
FDA approval of Adaptimmune's Tecelra for synovial sarcoma
unresectable or metastatic synovial sarcomasource ↗
▲Label ExpansionFDA Decision
Two previously approved Cryoport-supported therapies received new approvals to move to earlier lines of treatment
●Manufacturing MilestoneCMC / Inspection
IntegriCell cryopreservation centers expected fully operational and ready for validation in Q2 2024
▲Timing GuidancePresentation
Up to 5 new therapy approvals and 3 label/geographic expansions expected in remainder of 2024
Past FDA Catalysts and PDUFA Decisions
How CYRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CYRX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SHELTON JERRELLDirector, Officer (President, CEO) | Sell | -28,800 1,201,814 held | $14.91 | 08/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CYRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.8 % | 7.98 M | 508.32 K |
CYRX Institutional Ownership Trends
CYRX Short Interest
Shares sold short, counted twice a month.
4.88%
Short % of Float
of tradable shares sold short
2.4M
Shares Sold Short
-15.2% vs prior count
3.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
698.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CYRX ranks across every disease it competes in
Competitive Position is a premium feature
See how CYRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCYRX News
-CYRX
Oct 22, 2026▼ -2.8%today
Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026
Cryoport, Inc. will announce its financial results for Q3 2026 on November 5, 2026. A review document detailing key operational developments will be released alongside the earnings report. Management will host a conference call at 5:00 p.m. ET to answer questions from the investment community.
Read more →-CYRX
Aug 6, 2026Cryoport Reports Second Quarter 2026 Financial Results
Cryoport, Inc. reported an 8% year-over-year revenue increase to $49.0 million for Q2 2026, driven by strong growth in Life Sciences Services and BioStorage/BioServices. The company achieved positive adjusted EBITDA, indicating progress towards profitability. Despite a net loss of $8.3 million, Cryoport supported a record number of clinical trials and anticipates further growth from new product launches and expansions.
Read more →-CYRX
Jul 23, 2026Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
Cryoport, Inc. will announce its financial results for the second quarter of 2026 on August 6, 2026, following U.S. market closure. A detailed review document will be available prior to a conference call scheduled for the same day. The call aims to address investor questions regarding the company's performance and outlook.
Read more →-CYRX
Jun 25, 2026Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
Cryoport's IntegriCell cryopreservation services have been chosen by Verismo Therapeutics to support their KIR-CAR T cell therapy programs, specifically SynKIR-110 and SynKIR-310, both currently in Phase 1 clinical trials. The partnership aims to enhance the efficiency and reliability of the manufacturing process. IntegriCell's services will help Verismo maintain regulatory compliance while improving scalability for future clinical milestones.
Read more →-CYRX
May 4, 2026Cryoport Reports First Quarter 2026 Financial Results First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting cont
Cryoport, a leading provider of temperature-controlled supply chain solutions, reported a 16% increase in revenue for Q1 2026, totaling $47.8 million. The company's commercial support for cell and gene therapies grew by 26%, indicating strong market demand. As part of its growth strategy, Cryoport plans to expand its operations with new Global Supply Chain Centers in Paris and California. The firm has also raised its revenue guidance for the year, reflecting optimism about sustained growth in the future.
Read more →-CYRX
Apr 20, 2026Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
Cryoport, Inc. will report its financial results for Q1 2026 on May 4, 2026. A review document will accompany the earnings release, and a conference call will follow to address investor questions. The company emphasizes its role in providing integrated temperature-controlled supply chain solutions for the life sciences.
Read more →-CYRX
Mar 3, 2026Fourth Quarter and Full-Year 2025 Financial Results
Cryoport, Inc. (NASDAQ: CYRX) announced its financial results for Q4 and FY 2025, reporting a significant increase in revenue to $176.2 million, surpassing previous guidance. The company's Life Sciences Services revenue saw an 18% growth year-over-year, bolstered by a 29% rise in revenue from commercial cell and gene therapies. Cryoport supported a record 760 global clinical trials and established strategic partnerships to enhance its market position. Looking ahead, the company projects a revenue range of $190 million to $194 million for FY 2026.
Read more →-CYRX
Nov 4, 2025Cryoport Reports Third Quarter 2025 Financial Results Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences
Cryoport, Inc. has reported a 15% increase in third-quarter revenue, reaching $44.2 million, with significant contributions from cell and gene therapies. The company experienced notable growth in both Life Sciences Services and Products segments, with the former growing by 16% year-over-year. CEO Shelton indicated that the firm is well-positioned for profitability, raising its full-year revenue guidance due to promising performance and expansion initiatives. Additionally, a partnership with DHL is expected to enhance operations in the EMEA and APAC regions.
Read more →-CYRX
Aug 5, 2025▼ -5.9%on this news· ran to +22% by day 1
Cryoport Reports Second Quarter 2025 Financial Results
Cryoport, Inc. reported a 14% increase in total revenue for Q2 2025, totaling $45.5 million, boosted by a 33% rise in revenue from supporting commercial cell and gene therapies. The company's Life Sciences Services revenue also showed robust growth, with a 21% year-over-year increase. A strategic partnership with DHL aims to enhance Cryoport's global biologistics capabilities while the company reaffirms its full-year revenue guidance, indicating confidence in sustainable profitability moving forward. The overall performance underscores Cryoport's strong positioning within the regenerative medicine market.
Read more →-CYRX
Jun 12, 2025Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group
Cryoport, Inc. has completed the divestiture of its specialty courier business, CRYOPDP, to DHL Group, receiving around $200 million in cash. In addition, Cryoport and DHL have formed a strategic partnership to enhance supply chain service offerings for the life sciences sector. This collaboration aims to leverage Cryoport's expertise along with DHL's global logistics infrastructure, particularly in regions like Asia Pacific and EMEA. The company anticipates that this move will improve its growth trajectory and ensure a stronger position in the evolving market for regenerative medicine.
Read more →-CYRX
May 7, 2025Cryoport Reports First Quarter 2025 Financial Results Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Suppo
Cryoport, Inc. reported its financial results for the first quarter of 2025, achieving revenues of $41 million from continuing operations, reflecting a 10% increase compared to the previous year. The company also highlighted a 33% increase in revenues from supporting commercial Cell & Gene therapies. CEO Jerrell Shelton expressed optimism regarding future growth and stability within their services. Additionally, a strategic partnership with DHL is expected to further enhance operational capabilities, particularly in the APAC and EMEA regions.
Read more →-CYRX
Mar 31, 2025DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL DHL, BONN, Germany and Cryoport,
DHL Group has announced its acquisition of 100% of CRYOPDP, a specialty courier that specializes in logistics for clinical trials and biopharmaceuticals. This move aims to bolster DHL's capabilities in the life sciences and healthcare sectors as part of its strategy to be a leader in related logistics services by 2030. Additionally, a strategic partnership with Cryoport has been established to further enhance their supply chain offerings. The deal underscores DHL's commitment to improving service levels and expanding its global footprint in the healthcare logistics market.
Read more →-CYRX
Mar 4, 2025▲ +5.5%on this news· ran to +38% by day 1
Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results
Cryoport, Inc. reported its financial results for Q4 and FY 2024, with total revenue reaching $228.4 million, consistent with prior guidance. Notably, revenue from commercial Cell & Gene therapies increased by 20% for the fiscal year, highlighting growth in that sector. The company also reported a 45.8% gross margin for Q4 2024, an improvement from the same period last year. However, total revenue saw a slight decrease compared to FY 2023, primarily due to a decline in Life Sciences Products revenue. Cryoport aims for a revenue increase to between $240 - $250 million in FY 2025 based on ongoing strategic initiatives.
Read more →-CYRX
Nov 7, 2024Cryoport Reports Third Quarter 2024 Financial Results Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global cli
Cryoport, Inc. reported its third quarter financial results for 2024, showing a 9% increase in Life Sciences Services revenue and a 12% rise in BioStorage/BioServices revenue compared to the previous year. The company maintains its full-year revenue forecast of $225 million to $235 million despite a decline in Life Sciences Products revenue. CEO Jerrell Shelton highlighted strategic cost reduction measures and the launch of a new cryopreservation solution as key steps towards achieving sustainable profitability by 2025. However, challenges in product sales and external market conditions remain a concern.
Read more →-CYRX
Aug 6, 2024Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes $200 million repurchase program authorized to repurchase common stock and/or convertible notes Repurchasin
Cryoport, Inc. has announced a new repurchase program authorized for up to $200 million, which will be effective from August 1, 2024, through December 31, 2027. In addition, the company is repurchasing $160 million of its Convertible Senior Notes due in 2026, which is part of the new program and will strengthen its balance sheet. The repurchases are expected to close on August 9, 2024, while the company retains a substantial amount of liquidity to support long-term goals. Overall, these actions reflect Cryoport's strategic focus on debt management and long-term financial stability.
Read more →-CYRX
Aug 6, 2024Cryoport Reports Second Quarter 2024 Financial Results Revenue improved sequentially across all businesses Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total of 684 gl
Cryoport, Inc. reported its financial results for Q2 2024, highlighting a sequential increase in revenue across all business segments. The company's commercial Cell & Gene Therapy revenue saw a significant boost of 51% compared to the previous year. However, the Life Sciences Products division experienced a decline due to lower demand. The company has revised its full-year revenue guidance to a range of $225 million to $235 million, citing ongoing operational improvements and cost management initiatives.
Read more →-CYRX
May 7, 2024Cryoport Reports First Quarter 2024 Financial Results Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A t
Cryoport, Inc. announced its Q1 2024 financial results, reporting total revenue of $54.6 million, a 13% decrease from the previous year. The Company noted a 9% increase in revenues from its Commercial Cell & Gene Therapy sector. Despite a challenging global environment leading to disappointing results for Life Sciences Products, the CEO expressed optimism about potential revenue growth as new therapies gain approvals. The Company is maintaining its full-year revenue guidance while implementing cost-cutting measures in light of current economic conditions.
Read more →-CYRX
Mar 12, 2024Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results FY 2023 revenue of $233.3 million, in-line with guidance Year- over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices reven
Cryoport, Inc. reported FY 2023 financial results, achieving total revenues of $233.3 million, which fell within their guidance range. The company saw notable growth in its service sectors, particularly in Cell & Gene Therapy, which increased by 33% from the previous year. Additionally, Cryoport supported a record number of clinical trials, indicating strong demand for its services, while facing challenges in product revenues and slight revenue declines in certain segments. Looking ahead, the company anticipates continued revenue growth in 2024, propelled by strategic investments and industry trends.
Read more →-CYRX
Nov 8, 2023Cryoport Reports Third Quarter 2023 Financial Results Third quarter 2023 commercial Cell and Gene Therapy revenue up 54% year-over-year Supporting a record total of 670 clinical trials worldwide, with 81 in Phase 3 Nine
Cryoport, Inc. reported its financial results for the third quarter and the first nine months of 2023, showcasing a 54% increase in commercial cell and gene therapy revenue year-over-year. Despite a 7% decrease in total revenue for Q3, the company achieved strong gross margins and supported a record number of clinical trials. Furthermore, Cryoport announced strategic partnerships and an acquisition aimed at bolstering its market position. However, operating costs have risen substantially due to increased investments in infrastructure and technology.
Read more →-CYRX
Aug 9, 2023Cryoport Reports Second Quarter 2023 Financial Results Second quarter revenue of $57 million, in line with previously announced preliminary results Clinical trials supported by Cryoport increased to a record 668 global c
Cryoport, Inc. announced its Q2 2023 financial results, reporting a revenue of $57 million, which marks an 11% decrease compared to Q2 2022. The decline in revenue was largely attributed to a 67% drop in business from its MVE Biological Solutions segment in China. Despite this short-term challenge, the company highlighted its expansion in clinical trials and revenue growth in certain segments, including bioservices. Looking forward, Cryoport remains optimistic about its long-term growth strategies in the cell and gene therapy market.
Read more →About CryoPort, Inc. Common Stock
Headquarters112 WESTWOOD PLACE, SUITE 350, BRENTWOOD, TN, 37027
BIOPHARMAWATCH ELITE PLUS
Trade the next CYRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime